Skip to main content

Advertisement

SpringerLink
Log in

I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator

  • Published:
Journal of Nuclear Cardiology Aims and scope

Abstract

Background

Iodine 123 metaiodobenzylguanidine (MIBG) imaging and heart rate variability (HRV) analysis were compared in patients with an implantable cardioverter defibrillator (ICD) who did and did not receive defibrillator discharges. Although the ICD has been shown to abort potentially fatal ventricular arrhythmias, identification of patients who most benefit from this device remains difficult. As the autonomic nervous system has been implicated in the genesis of these arrhythmias, we undertook a pilot study to evaluate local myocardial sympathetic innervation with the use of I-123 MIBG myocardial imaging, as well as central autonomic tone with the use of HRV, in patients with implantable defibrillators. Test results were correlated with the occurrence of ICD discharges.

Methods and Results

Seventeen patients with previously implanted defibrillators were studied. Of these, 10 had at least 1 appropriate device discharge for ventricular tachyarrhythmias, whereas 7 had no discharge. Patients with a discharge had a significantly lower I-123 MIBG heart-mediastinal tracer uptake ratio, higher I-123 MIBG defect scores, more extensive sympathetic denervation, and significantly reduced values for several HRV parameters, particularly those in the frequency domain. When combined, the I-123 MIBG heart-mediastinal ratio and HRV 5-minute low-frequency variables were highly predictive of defibrillator discharges. All patients with a heart-mediastinal ratio lower than 1.54 and 5-minute low frequency lower than 443 ms2 had an ICD discharge (4/4), whereas no patient with an uptake ratio greater than 1.54 and 5-minute low frequency greater than 443 ms2 did (0/3, P = .03).

Conclusions

Cardiac autonomic assessment using a combination of myocardial scintigraphic and neurophysiologic techniques may help select patients who would most benefit from an implantable defibrillator by identifying those at increased risk for potentially fatal arrhythmias. (J Nucl Cardiol 2003;10:121-31.)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Myerburg RJ, Castellanos A. Cardiac arrest and sudden death. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia: Saunders; 1997. p. 742–79.

    Google Scholar 

  2. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998; 98:2334–51.

    PubMed  CAS  Google Scholar 

  3. O’Brien BJ, Connolly SJ, Goeree R, et al, for the CIDS investigators. Cost-effectiveness of the implantable cardioverterdefibrillator. Results from the Canadian Defibrillator Study (CIDS). Circulation 2001;103:1416–21.

    PubMed  CAS  Google Scholar 

  4. Moss AJ, Hall WJ, Cannon DS, et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996;335:1933–40.

    Article  PubMed  CAS  Google Scholar 

  5. Buxton AE, Lee KL, Fisher JD, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882–90.

    Article  PubMed  CAS  Google Scholar 

  6. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–83.

    Article  Google Scholar 

  7. Kuck K, Cappato R, Siebels J, Rüppel R, for the CASH Investigators. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748–54.

    PubMed  CAS  Google Scholar 

  8. Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.

    Article  PubMed  Google Scholar 

  9. Exner DV, Klein GJ, Prystowsky EN. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease. Circulation 2001;104:1564–70.

    Article  PubMed  CAS  Google Scholar 

  10. Bigger JT. Expanding indications for implantable cardiac defibrillators. N Engl J Med 2002;346:931–2.

    Article  PubMed  Google Scholar 

  11. Hallstrom AP, McAnulty JH, Wilkoff BL, et al, and the Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Circulation 2001;37:1093–9.

    CAS  Google Scholar 

  12. Zipes DP. A century of cardiac arrhythmias. J Am Coll Cardiol 1999;34:959–65.

    Article  PubMed  CAS  Google Scholar 

  13. Zipes DP, Wellens HJJ. What have we learned about cardiac arrhythmias? Circulation 2000;102:IV52–7.

    PubMed  CAS  Google Scholar 

  14. Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996;27:1053–60.

    Article  PubMed  CAS  Google Scholar 

  15. Barron HV, Viskin S. Autonomic markers and prediction of cardiac death after myocardial infarction. Lancet 1998;351:461–22.

    Article  PubMed  CAS  Google Scholar 

  16. The Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043–65.

    Google Scholar 

  17. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med 2000;27:1–6.

    Article  PubMed  CAS  Google Scholar 

  18. Merlet P, Valette H, Dubois-Randé JL, et al. Prognostic value of cardiac MIBG imaging in patients with heart failure. J Nucl Med 1992;33:471–7.

    PubMed  CAS  Google Scholar 

  19. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579–900.

    Article  PubMed  CAS  Google Scholar 

  20. Kleiger RE, Miller JP, Bigger JT, Moss AJ, and the Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256–62.

    Article  PubMed  CAS  Google Scholar 

  21. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signalaveraged electrocardiogram. J Am Coll Cardiol 1991;18:687–97.

    PubMed  CAS  Google Scholar 

  22. Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. Circulation 1993;88:927–34.

    PubMed  CAS  Google Scholar 

  23. Mitrani RD, Klein LS, Miles WM, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 1993;22:1344–53.

    Article  PubMed  CAS  Google Scholar 

  24. Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-MIBG. J Am Coll Cardiol 1989;14:1519–266.

    Article  PubMed  CAS  Google Scholar 

  25. Bigger JT Jr, Fleiss JL, Steinman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164–71.

    PubMed  Google Scholar 

  26. Morozumi T, Kusuoka H, Fukuchi K, et al. Myocardial iodine- 123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med 1997;38:49–52.

    PubMed  CAS  Google Scholar 

  27. Lotze U, Kober A, Kaepplinger S, et al. Cardiac sympathetic activity as measured by myocardial 123-I-metaiodobenzylguanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:1548–51.

    Article  PubMed  CAS  Google Scholar 

  28. Hohnsloser SH, Klingenheben T, Li YG, et al. T-wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD patients: prospective comparison with conventional risk markers. J Cardiovasc Electrophysiol 1998;9:1258–68.

    Article  Google Scholar 

  29. Port SC, editor. Imaging guidelines for nuclear cardiology procedures. Part 2. J Nucl Cardiol 1999;6:G70–1.

    Article  Google Scholar 

  30. Huikuri HV, Castellanos A, Myerberg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473–82.

    Article  PubMed  CAS  Google Scholar 

  31. Echt DS, Liebson PR, Mitchell LB, et al, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–8.

    PubMed  CAS  Google Scholar 

  32. Waldo AL, Camm AJ, deRuyter H, et al, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7–12.

    Article  PubMed  CAS  Google Scholar 

  33. Singh SH, Fletcher RD, Fisher SG, et al, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and symptomatic ventricular arrhythmias. N Engl J Med 1995;333:77–82.

    Article  PubMed  CAS  Google Scholar 

  34. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998;97:1514–21.

    PubMed  CAS  Google Scholar 

  35. Engelstein E, Sawada SG, Hutchins GD, et al. Sympathetic denervation in patients following acute myocardial infarction. Relationship to myocardial perfusion and metabolism [abstract]. J Am Coll Cardiol 1998;31:526A.

    Article  Google Scholar 

  36. La Rovere MT, Bigger JT Jr, Marcus FI, et al, on behalf of the ATRAMI Investigators. Prognostic value of depressed baroreflex sensitivity: the ATRAMI study [abstract]. Circulation 1995; 92(Suppl I):I-676.

    Google Scholar 

  37. Zipes DP. Sympathetic stimulation and arrhythmias. N Engl J Med 1991;325:656–7.

    PubMed  CAS  Google Scholar 

  38. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40:917–23.

    PubMed  CAS  Google Scholar 

  39. Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252–8.

    PubMed  CAS  Google Scholar 

  40. Gioia G, Bagheri B, Gottlieb CD, et al. Prediction of outcome of patients with life-threatening ventricular arrhythmias treated with automatic implantable cardioverter-defibrillators using SPECT perfusion imaging. Circulation 1997;95:390–4.

    PubMed  CAS  Google Scholar 

  41. Gradel C, Jain D, Batsford WP, Wackers FJT, Zaret BL. Relationship of scar and ischemia to the results of programmed electrophysiological stimulation in patients with coronary artery disease. J Nucl Cardiol 1997;4:379–86.

    Article  PubMed  CAS  Google Scholar 

  42. Bigger JT. Clinical assessment of the autonomic nervous system. In: Topol EJ, editor. Comprehensive cardiovascular medicine. Philadelphia: Lippincott-Raven; 1998. p. 2185–205.

    Google Scholar 

  43. Casadei B, Cochrane S, Johnston J, et al. Pitfalls in interpretation of spectral analysis of the heart rate variability during exercise in humans. Acta Physiol Scand 1995;153:125–31.

    Article  PubMed  CAS  Google Scholar 

  44. Lombardi F, Malliani A, Pagani M, Cerutti S. Heart rate variability and its sympatho-vagal modulation. Cardiovasc Res 1996;32:208–16.

    Article  PubMed  CAS  Google Scholar 

  45. Lombardi F. Frequency domain analysis of HRV. In: Zareba W, Maison-Blanche P, Locati E, editors. Noninvasive electrocardiology in clinical practice. New York: Futura; 2001. p. 163–80.

    Google Scholar 

  46. Moss AJ, Stern S. Noninvasive electrocardiography: clinical aspects of holter monitoring. London: Saunders; 1996.

    Google Scholar 

  47. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;79:1645–50.

    Article  PubMed  CAS  Google Scholar 

  48. Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin converting enzyme inhibitor therapy. J Nucl Med 1999;40:217- 23.

    PubMed  CAS  Google Scholar 

  49. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085–9.

    PubMed  CAS  Google Scholar 

  50. Lotze U, Kaepplinger S, Kober A, et al. Recovery of the cardiac adrenergic nervous system after long-term β blocker therapy in idiopathic dilated cardiomyopathy: assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001;42:49–54.

    PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Rishi Arora

    Present address: Krannert Institute of Cardiology, Indianapolis, Ind

Authors and Affiliations

  1. Division of Cardiology and Department of Nuclear Medicine, Montefiore Medical Center, 111 E 210th St, 10467-2490, Bronx, NY

    Rishi Arora, Kevin J. Ferrick, Robert C. Kaplan, Michael Rozengarten, Farhana Latif, Kaman Ng, Vanessa Marcano, Sherman Heller, John D. Fisher & Mark I. Travin

  2. Division of Cardiology and Second Department of Internal Medicine (Cardiology), Sapporo Medical University School of Medicine, Sapporo, Japan

    Tomoaki Nakata

Authors
  1. Rishi Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin J. Ferrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomoaki Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert C. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Rozengarten
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Farhana Latif
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kaman Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vanessa Marcano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sherman Heller
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. John D. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mark I. Travin
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by Daiichi Radioisotope Laboratories, Ltd, Tokyo, Japan, and MDS Nordion, Ottawa, Ontario, Canada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arora, R., Ferrick, K.J., Nakata, T. et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 10, 121–131 (2003). https://doi.org/10.1067/mnc.2003.2

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1067/mnc.2003.2

Key Words

Search

Navigation